The long-term survival of a patient with neuroblastoma suggests the personalized cancer treatment may work for solid tumors, not just blood cancers.
Among 19 neuroblastoma patients treated with CAR T-cell therapy, eight survived more than 5 years after infusion, including five with follow-up of more than 13 years, reported Helen Heslop ...
Helen Heslop and colleagues conducted a phase 1 clinical trial involving 19 children with neuroblastoma, between 2004 and 2009, during which they tested T cells that were engineered to recognize ...
so that she’s grown up and is leading a normal life,” Professor Helen Heslop, co-author of the research from Houston’s Baylor College of Medicine and the director of the Center for Cell and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results